tiprankstipranks
Trending News
More News >
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
US Market
Advertisement

LENZ Therapeutics (LENZ) Stock Statistics & Valuation Metrics

Compare
184 Followers

Total Valuation

LENZ Therapeutics has a market cap or net worth of $891.39M. The enterprise value is $899.93M.
Market Cap$891.39M
Enterprise Value$899.93M

Share Statistics

LENZ Therapeutics has 28,146,154 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,146,154
Owned by Insiders20.01%
Owned by Institutions0.32%

Financial Efficiency

LENZ Therapeutics’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -28.45%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.45%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-8.29M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio4.75
Price to Fair Value3.01
Price to FCF-17.91
Price to Operating Cash Flow-17.71
PEG Ratio-0.30

Income Statement

In the last 12 months, LENZ Therapeutics had revenue of 0.00 and earned -49.77M in profits. Earnings per share was -2.34.
Revenue0.00
Gross Profit-58.00K
Operating Income-58.61M
Pretax Income-49.77M
Net Income-49.77M
EBITDA-49.71M
Earnings Per Share (EPS)-2.34

Cash Flow

In the last 12 months, operating cash flow was -51.50M and capital expenditures -578.00K, giving a free cash flow of -52.08M billion.
Operating Cash Flow-51.50M
Free Cash Flow-52.08M
Free Cash Flow per Share-1.85

Dividends & Yields

LENZ Therapeutics pays an annual dividend of $7.21, resulting in a dividend yield of ―
Dividend Per Share$7.21
Dividend Yield
Payout Ratio-21.57%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.71
52-Week Price Change23.88%
50-Day Moving Average30.85
200-Day Moving Average28.18
Relative Strength Index (RSI)43.97
Average Volume (3m)307.08K

Important Dates

LENZ Therapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateJul 30, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend DateMar 22, 2024

Financial Position

LENZ Therapeutics as a current ratio of 20.36, with Debt / Equity ratio of 0.62%
Current Ratio20.36
Quick Ratio20.36
Debt to Market Cap<0.01
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00

Taxes

In the past 12 months, LENZ Therapeutics has paid 1.00K in taxes.
Income Tax1.00K
Effective Tax Rate>-0.01

Enterprise Valuation

LENZ Therapeutics EV to EBITDA ratio is -11.98, with an EV/FCF ratio of -9.95.
EV to Sales0.00
EV to EBITDA-11.98
EV to Free Cash Flow-9.95
EV to Operating Cash Flow-10.03

Balance Sheet

LENZ Therapeutics has $193.98M in cash and marketable securities with $1.18M in debt, giving a net cash position of -$192.79M billion.
Cash & Marketable Securities$193.98M
Total Debt$1.18M
Net Cash-$192.79M
Net Cash Per Share-$6.85
Tangible Book Value Per Share$9.59

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for LENZ Therapeutics is $49.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$49.60
Price Target Upside56.62% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast
EPS Growth Forecast68.93%

Scores

Smart Score8
AI Score46
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis